Literature DB >> 25583715

Molecular characterization of the cytochrome b gene and in vitro atovaquone susceptibility of Plasmodium falciparum isolates from Kenya.

Luicer A Ingasia1, Hoseah M Akala1, Mabel O Imbuga2, Benjamin H Opot1, Fredrick L Eyase1, Jacob D Johnson1, Wallace D Bulimo1, Edwin Kamau3.   

Abstract

The prevalence of a genetic polymorphism(s) at codon 268 in the cytochrome b gene, which is associated with failure of atovaquone-proguanil treatment, was analyzed in 227 Plasmodium falciparum parasites from western Kenya. The prevalence of the wild-type allele was 63%, and that of the Y268S (denoting a Y-to-S change at position 268) mutant allele was 2%. There were no pure Y268C or Y268N mutant alleles, only mixtures of a mutant allele(s) with the wild type. There was a correlation between parasite 50% inhibitory concentration (IC50) and parasite genetic polymorphism; mutant alleles had higher IC50s than the wild type.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25583715      PMCID: PMC4325819          DOI: 10.1128/AAC.03956-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa.

Authors:  Eli Schwartz; Shay Bujanover; Kevin C Kain
Journal:  Clin Infect Dis       Date:  2003-07-18       Impact factor: 9.079

2.  Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.

Authors:  Anna Färnert; Johan Lindberg; Pedro Gil; Göte Swedberg; Yngve Berqvist; Mita M Thapar; Niklas Lindegårdh; Sándor Berezcky; A Björkman
Journal:  BMJ       Date:  2003-03-22

3.  Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand.

Authors:  S Looareesuwan; C Viravan; H K Webster; D E Kyle; D B Hutchinson; C J Canfield
Journal:  Am J Trop Med Hyg       Date:  1996-01       Impact factor: 2.345

4.  1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-06-27

5.  Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites.

Authors:  I K Srivastava; J M Morrisey; E Darrouzet; F Daldal; A B Vaidya
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

6.  Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.

Authors:  Lise Musset; Bruno Pradines; Daniel Parzy; Rémy Durand; Patricia Bigot; Jacques Le Bras
Journal:  J Antimicrob Chemother       Date:  2005-11-30       Impact factor: 5.790

7.  Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening.

Authors:  Martin Smilkstein; Nongluk Sriwilaijaroen; Jane Xu Kelly; Prapon Wilairat; Michael Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Atovaquone/proguanil resistance in Africa: a case report.

Authors:  Kim P David; Michael Alifrangis; Ali Salanti; Lasse S Vestergaard; Anita Rønn; I B Bygbjerg
Journal:  Scand J Infect Dis       Date:  2003

9.  Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.

Authors:  Gabrielle Fröberg; Pedro Eduardo Ferreira; Andreas Mårtensson; Abdullah Ali; Anders Björkman; José Pedro Gil
Journal:  Antimicrob Agents Chemother       Date:  2012-12-03       Impact factor: 5.191

10.  Identification of malaria transmission and epidemic hotspots in the western Kenya highlands: its application to malaria epidemic prediction.

Authors:  Christine L Wanjala; John Waitumbi; Guofa Zhou; Andrew K Githeko
Journal:  Parasit Vectors       Date:  2011-05-19       Impact factor: 3.876

View more
  5 in total

Review 1.  Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.

Authors:  Benjamin Blasco; Didier Leroy; David A Fidock
Journal:  Nat Med       Date:  2017-08-04       Impact factor: 53.440

2.  Selection of Plasmodium falciparum cytochrome B mutants by putative PfNDH2 inhibitors.

Authors:  Kristin D Lane; Jianbing Mu; Jinghua Lu; Sean T Windle; Anna Liu; Peter D Sun; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

3.  Saccharomyces cerevisiae-based mutational analysis of the bc1 complex Qo site residue 279 to study the trade-off between atovaquone resistance and function.

Authors:  Zehua Song; Jérôme Clain; Bogdan I Iorga; Zhou Yi; Nicholas Fisher; Brigitte Meunier
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

4.  Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.

Authors:  Henry M Staines; Rebekah Burrow; Beatrix Huei-Yi Teo; Irina Chis Ster; Peter G Kremsner; Sanjeev Krishna
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

5.  Decoding the Molecular Effects of Atovaquone Linked Resistant Mutations on Plasmodium falciparum Cytb-ISP Complex in the Phospholipid Bilayer Membrane.

Authors:  Lorna Chebon-Bore; Taremekedzwa Allan Sanyanga; Colleen Varaidzo Manyumwa; Afrah Khairallah; Özlem Tastan Bishop
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.